Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dutogliptin - Recardio

Next Previous
X
Search
Drug Profile

Dutogliptin - Recardio

Alternative Names: Dutogliptin tartrate; PHX-1149; PHX1149T; REC-01

Latest Information Update: 05 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phenomix Corporation
  • Developer Phenomix Corporation; RECARDIO
  • Class Antihyperglycaemics; Ischaemic heart disorder therapies; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Myocardial infarction
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 31 May 2023 Recardio plans a phase III trial for Myocardial infarction (In adults, In the elderly, Combination therapy) (SC,Injection) in September 2023 (NCT05881382)
  • 19 May 2021 Recardio completes phase II trial in Myocardial Infarction (Combination therapy) in Austria, Belgium, Hungary, the Netherlands and Poland (SC)
  • 19 Feb 2021 Dutogliptin is still in phase II trials for Myocardial infarction (Combination therapy) in Austria, Belgium, Hungary, the Netherlands, Poland (SC) (NCT03486080)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top